NCT04841148 - Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

May 31, 2028

Conditions

Breast Cancer

Interventions

DRUG

HCQ

600 mg tablets twice daily D1-28 of each 28-day cycle

DRUG

Avelumab

10 mg/kg, IV, D1 and D15 of each 28-day cycle

DRUG

Palbociclib

125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.

Trial Locations (7)

RECRUITING

University of Pennsylvania, Philadelphia

RECRUITING

Georgetown University, Washington D.C.

RECRUITING

Vanderbilt University, Nashville

RECRUITING

Indiana University, Indianapolis

RECRUITING

University of Chicago, Chicago

RECRUITING

University of Washington, Seattle

RECRUITING

Dana-Farber Cancer Institute, Boston